1. Pink Sheet

Humana's Re-Balancing Act

 
• By Michael McCaughan

Is Medicare turning into a bad business for Humana? That surprising question may dog the company heading into 2007-and the answer may be pivotal to the viability of the private insurance-based drug benefit.

Humana Inc.’s dramatic expansion under Medicare has fueled enormous growth at the company, with revenues for the third quarter jumping nearly 50% to $5.65 billion, thanks to soaring membership in Humana’s Medicare Advantage managed care plans—and the more than 3.5 million enrollees in Humana’s brand new stand-alone prescription drug business.

But the company’s success in Medicare is putting it in a bit of a bind. On the one hand, as...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

More from Pink Sheet

Here At Last: Canada’s Long-Contested Guidelines For Curbing Excessive Drug Prices

 
• By Neena Brizmohun

Final guidelines explaining how staff at Canada’s Patented Medicine Prices Review Board should go about identifying drugs that could be considered for an excessive price hearing will come into force soon.

Denmark Sets New EU Benchmark With 14-Day Clinical Trial Review Timeline

 
• By Vibha Sharma

Denmark is shaking up clinical trial timelines with a new process for reviewing applications for early-phase mono-national trials that is twice as fast as the standard timelines in the EU and the UK.

US Budget Bill Eases IRA Price Controls But Coverage Losses Will Impact Pharma

 
• By Cathy Kelly

The legislation expected to be signed by President Trump is a mixed bag for pharmaceutical manufacturers depending on their product mix and manufacturing situation.